← Evidence map

ArticleFEBS open bio2026

Treatment with KCL-286, a first-in-class retinoic acid receptor-β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease.

Natasha Hill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Treatment with KCL-286, a first-in-class retinoic acid receptor-β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease. | Socratic